Sumac (Rhus coriaria L.) capsules and Mefenamic acid and the amount of bleeding and quality of life in women with menorrhagia

Comparison of the effects of Sumac (Rhus coriaria L.) capsules and Mefenamic acid on the amount of bleeding and quality of life in women with menorrhagia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181024041449N6

Enrollment

150

Registered

2025-12-21

Start date

2016-12-21

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

menorrhagia. Excessive and frequent menstruation with regular cycle

Interventions

Intervention 1: Intervention group: Mefenamic acid capsule 250 mg every 8 hours and Sumac capsule 3 g daily. Intervention 2: Control group: Mefenamic acid capsule 250 mg every 8 hours and placebo caps

Eligibility

Sex/Gender

Female

Age

18 Years to 48 Years

Inclusion criteria

Inclusion criteria: Age 18–48 years Body Mass Index (BMI) range: 5/18–9/29 Regular menstrual cycle Diagnosis of menorrhagia based on the Pictorial Blood Loss Assessment Chart (PBAC)

Exclusion criteria

Exclusion criteria: Allergy to sumac Presence of a specific disease Pregnancy or intention to become pregnant within the next three months Breastfeeding Presence of systemic diseases (thyroid, liver, coagulation disorders) — abnormal Pap smear or ultrasound findings including endometrial hyperplasia, fibroid, polyp.

Design outcomes

Primary

Measure	Time frame
Bleeding. Timepoint: during the year 2005. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLobat Jfarzadeh

Shahre-kord University of Medical Sciences

jafarzade@skums.ac.ir+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026